OBJECTIVE: To develop and evaluate a pharmacogenomics information resource for pharmacists. MATERIALS AND METHODS: We built a pharmacogenomics information resource presenting Food and Drug Administration (FDA) drug product labelling information, refined it based on feedback from pharmacists, and conducted a comparative usability evaluation, measuring task completion time, task correctness and perceived usability. Tasks involved hypothetical clinical situations requiring interpretation of pharmacogenomics information to determine optimal prescribing for specific patients. RESULTS: Pharmacists were better able to perform certain tasks using the redesigned resource relative to the Pharmacogenomic Knowledgebase (PharmGKB) and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. On average, participants completed tasks in 107.5 s using our resource, compared to 188.9 s using PharmGKB and 240.2 s using the FDA table. Using the System Usability Scale, participants rated our resource 79.62 on average, compared to 53.27 for PharmGKB and 50.77 for the FDA table. Participants found the correct answers for 100% of tasks using our resource, compared to 76.9% using PharmGKB and 69.2% using the FDA table. DISCUSSION: We present structured, clinically relevant pharmacogenomic FDA drug product label information with visualizations to help explain the relationships between gene variants, drugs, and phenotypes. The results from our evaluation suggest that user-centered interfaces for pharmacogenomics information can increase ease of access and comprehension. CONCLUSION: A clinician-focused pharmacogenomics information resource can answer pharmacogenomics-related medication questions faster, more correctly, and more easily than widely used alternatives, as perceived by pharmacists.
OBJECTIVE: To develop and evaluate a pharmacogenomics information resource for pharmacists. MATERIALS AND METHODS: We built a pharmacogenomics information resource presenting Food and Drug Administration (FDA) drug product labelling information, refined it based on feedback from pharmacists, and conducted a comparative usability evaluation, measuring task completion time, task correctness and perceived usability. Tasks involved hypothetical clinical situations requiring interpretation of pharmacogenomics information to determine optimal prescribing for specific patients. RESULTS: Pharmacists were better able to perform certain tasks using the redesigned resource relative to the Pharmacogenomic Knowledgebase (PharmGKB) and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. On average, participants completed tasks in 107.5 s using our resource, compared to 188.9 s using PharmGKB and 240.2 s using the FDA table. Using the System Usability Scale, participants rated our resource 79.62 on average, compared to 53.27 for PharmGKB and 50.77 for the FDA table. Participants found the correct answers for 100% of tasks using our resource, compared to 76.9% using PharmGKB and 69.2% using the FDA table. DISCUSSION: We present structured, clinically relevant pharmacogenomic FDA drug product label information with visualizations to help explain the relationships between gene variants, drugs, and phenotypes. The results from our evaluation suggest that user-centered interfaces for pharmacogenomics information can increase ease of access and comprehension. CONCLUSION: A clinician-focused pharmacogenomics information resource can answer pharmacogenomics-related medication questions faster, more correctly, and more easily than widely used alternatives, as perceived by pharmacists.
Authors: Micheal Hewett; Diane E Oliver; Daniel L Rubin; Katrina L Easton; Joshua M Stuart; Russ B Altman; Teri E Klein Journal: Nucleic Acids Res Date: 2002-01-01 Impact factor: 16.971
Authors: Julie A Johnson; Amanda R Elsey; Michael J Clare-Salzler; David Nessl; Michael Conlon; David R Nelson Journal: Pharmacogenomics Date: 2013-05 Impact factor: 2.533
Authors: Grace M Kuo; Joseph D Ma; Kelly C Lee; James R Halpert; Philip E Bourne; Theodore G Ganiats; Palmer Taylor Journal: Pharmacogenomics Date: 2011-02 Impact factor: 2.533
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Simon de Denus; Nathalie Letarte; Thierry Hurlimann; Jean-Philippe Lambert; Annie Lavoie; Laura Robb; Nancy L Sheehan; Jacques Turgeon; Barbara Vadnais Journal: Pharmacogenomics Date: 2013-01 Impact factor: 2.533
Authors: Emily Beth Devine; Chia-Ju Lee; Casey L Overby; Neil Abernethy; Jeannine McCune; Joe W Smith; Peter Tarczy-Hornoch Journal: Int J Med Inform Date: 2014-05-09 Impact factor: 4.046
Authors: Casey Lynnette Overby; Angelika Ludtke Erwin; Noura S Abul-Husn; Stephen B Ellis; Stuart A Scott; Aniwaa Owusu Obeng; Joseph L Kannry; George Hripcsak; Erwin P Bottinger; Omri Gottesman Journal: J Pers Med Date: 2014-02-27
Authors: Kirsten Neudoerffer Kangelaris; Stephen Bent; Robert L Nussbaum; David A Garcia; Jeffrey A Tice Journal: J Gen Intern Med Date: 2009-03-21 Impact factor: 5.128